PMID: 8468441Jan 1, 1993Paper

The costs of depression

International Clinical Psychopharmacology
P Kind, J Sorensen

Abstract

Depression is one of the commonest conditions seen by general practitioners. Conventional treatments are typically drug based, and usually involve one of the tricyclic preparations. The evaluation of new treatments requires an understanding of the costs and benefits of existing alternatives, to provide a comparative framework for general practitioners and others concerned with the treatment and management of depressed patients. This paper presents estimates of the direct costs associated with the treatment of patients in England and Wales. These amount to some 420 million pounds annually. Pharmaceutical costs represent a relatively small proportion of this total. Substantial indirect costs are generated through lost productivity, and these may exceed 3 billion pounds.

Citations

Dec 20, 2005·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·H-H König, S Friemel
Apr 29, 2011·Social Psychiatry and Psychiatric Epidemiology·Sung Man ChangMaeng Je Cho
Sep 29, 2004·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Sophie Béjean, Hélène Sultan-Taïeb
Dec 9, 1995·Health Policy·K Smith, K Wright
Sep 4, 2012·Journal of Affective Disorders·Marina EconomouCostas N Stefanis
Sep 3, 2002·Journal of Affective Disorders·A P Van AmerongenA Tournoux
Mar 14, 2000·Maturitas·L W MaartensV J Pop
Sep 27, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·J Borghi, J F Guest
Nov 26, 1999·European Psychiatry : the Journal of the Association of European Psychiatrists·M C BrownJ F Guest
Jan 19, 2000·Epidemiologia e psichiatria sociale·J CascianoR Casciano
May 15, 2009·The Australian and New Zealand Journal of Psychiatry·Mitsuhiro SadoYutaka Ono
Dec 20, 2013·BMC Psychiatry·Mitsuhiro SadoKimio Yoshimura
Feb 16, 2013·ClinicoEconomics and Outcomes Research : CEOR·Claudio MencacciClaudio Ripellino
Jun 21, 2013·Neuropsychiatric Disease and Treatment·Mitsuhiro SadoKimio Yoshimura
Oct 7, 2011·The Primary Care Companion to CNS Disorders·Yasuyuki Okumura, Teruhiko Higuchi
Aug 2, 2003·The British Journal of Psychiatry : the Journal of Mental Science·Daniel ChisholmUNKNOWN LIDO Group
Aug 2, 2003·The British Journal of Psychiatry : the Journal of Mental Science·Jan Scott, Barbara Dickey
Jan 1, 2009·International Journal of Psychiatry in Clinical Practice·Feng XieKarina Hansen
Jan 1, 1999·International Journal of Psychiatry in Clinical Practice·M TregliaR L Dunn
Sep 14, 2006·Current Medical Research and Opinion·Márcio MachadoThomas R Einarson
Jun 8, 2002·Pharmacoepidemiology and Drug Safety·Deborah L AckermanMichael Gitlin
Jul 14, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·L FostickD Amital
May 10, 2005·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·P Andlin-Sobocki, H-U Wittchen
Aug 20, 2011·Psychiatry and Clinical Neurosciences·Mitsuhiro SadoTakehiko Kikkawa
Sep 6, 2006·Journal of Affective Disorders·Melanie LuppaSteffi G Riedel-Heller
May 7, 1998·Acta Psychiatrica Scandinavica·R Crott, P Gilis
Sep 23, 2000·International Journal of Psychiatry in Medicine·B J BurnsH C Schulberg
Oct 1, 1996·International Journal of Technology Assessment in Health Care·B Mårtensson
Apr 10, 1999·The Australian and New Zealand Journal of Psychiatry·T P Oei, A E Yeoh
Apr 23, 2002·The Journal of Mental Health Policy and Economics·Patrizia BertoFortunato Rizzo
Feb 24, 2001·International Clinical Psychopharmacology·A DubiniP Pancheri
Apr 27, 2004·International Clinical Psychopharmacology·Renee RomeoChristine Thomas
Aug 4, 2004·International Clinical Psychopharmacology·Thomas R Einarson
Feb 18, 2005·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Teh-wei Hu
Oct 17, 2002·PharmacoEconomics·Susan J Varney, Julian F Guest
Mar 2, 2002·The British Journal of Psychiatry : the Journal of Mental Science·Roben Das Gupta, Julian F Guest
Sep 5, 2001·The British Journal of Psychiatry. Supplement·J Mendlewicz
Mar 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·S M Skevington, A Wright
Sep 7, 2000·The British Journal of Psychiatry : the Journal of Mental Science·D ChisholmR S Murthy
Jun 1, 1996·The British Journal of Psychiatry : the Journal of Mental Science·S A MontgomeryM Clark
Apr 1, 1996·The British Journal of Psychiatry : the Journal of Mental Science·M HotopfC Normand

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.